Bextra Lawsuit Inquiry Form
: : Bextra News Blog
Bextra Litigation: Bextra suit filed in federal court
October 7, 2005 09:49
Like litigation in other Cox II matters, Bextra litigation appears to be moving forward as well.
St. Louis Attorney Jeffrey Lowe filed a complaint in U.S. District Court in East St. Louis on behalf of seven people seeking damages for personal injuries after taking the prescription pain reliever, Bextra.
Often claims are brought together to allow for consolidated discovery. That is, there is some safety in numbers. By bringing their Bextra litigationin one case, they can share the benefits of discovery and the costs of pursuing the discovery.
According to the complaint, "The defendants? actually knew of the defective nature of their product, yet continued to design, manufacture, market, distribute and sell their product to maximize sales and profits at the expense of the general public?s health and safety in conscious disregard of the foreseeable harm caused by Bextra."
Despite setbacks, painkillers are viewed as profit makers
September 19, 2005 17:08
By deciding that the Merck drug Vioxx contributed to the death of a Texas man, a jury on Friday dealt another punch to the battered class of arthritis painkillers known as cox-2 inhibitors. Merck withdrew Vioxx from the market last autumn over safety concerns, and Pfizer did the same thing a few months later with one of its cox-2 drugs, Bextra. http://www.iht.com/articles/2005/08/21/business/vioxx.php
Bextra suit filed in St. Clair County
July 19, 2005 06:47
May 5, 2005:
Claiming he suffered chest pains and heart attacks from taking the arthritis pain-relieving drug Bextra, Maurice Dulle filed a $300,000 suit against pharmaceuticals Pharmacia & Upjohn, G.D. Searle, Pfizer and a Troy pharmacy, Prescriptions Plus, in St. Clair County Circuit Court April 29.
Represented by Todd Hageman of Simon & Passanante of St. Louis and James Onder of Onder, Shelton, O'Leary & Peterson of St. Louis, Dulle alleges Bextra posed cardiovascular risk to patients, but consumers were led to believe that it was safe.
Direct-to-Consumer Advertising Continues To Trigger Consumer Action
June 6, 2005 11:15
Despite the abrupt withdrawal of Vioxx and, most recently, Bextra from the market, consumers continue to respond to direct-to-consumer advertising (DTCA) at levels comparable to those reported prior to the Vioxx recall, according to the latest findings from Ipsos PharmTrends, a syndicated tracking study of consumer behavior by Ipsos, the global survey-based marketing research firm.
Vioxx and Bextra already pulled from the market
June 6, 2005 11:14
Study casts more doubt on safety of popular pain killers
ANAHEIM, California (AP) With prescription drugs Vioxx and Bextra already pulled from the market, a study has raised disturbing questions about the heart safety of long-term use of over-the-counter pain relievers such as Advil, Motrin and Aleve.
Final Letter on Bextra
June 6, 2005 11:14
FDA Letter on Bextra from Pfizer - 10/15/2004